Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group have been sold in the UK.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department and NHS England do not hold information on the sales within the United Kingdom of the non-invasive pre-natal tests branded as NIFTY, manufactured by BGI Group. The NHS Supply Chain, who manage the sourcing, delivery, and supply of healthcare products, services, and food for National Health Service trusts and healthcare organisations across England, develop procurement frameworks which enable NHS organisations to buy goods and services from suppliers. NHS Supply Chain has confirmed that non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group, are not on their procurement framework.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps he is taking to ensure customers of Southern Water are able to install water efficiency measures in their meter chambers.
Answered by Robbie Moore - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
Southern Water is developing its next Water Resources Management Plan and its draft plan included the proposed to update water meters with smart meters across its customers by 2030 through an extensive replacement programme. The company plans to undertake 10,000 household water audits per year. The company is due to reconsult on its plan this summer. It will not be granted permission to finalise its plan until Defra are satisfied that it is appropriate, including assurance that the water efficiency programme is robust, sufficiently ambitious and enables customers to be efficient with the water they use.
Most water efficiency interventions by water companies are directed to water use within properties. Southern Water have not specified measures beyond smart metering that directly involve the meter chamber. Water meters are normally water company property and measures in the meter chamber would not usually be undertaken by customers.
Southern Water reported through its 2022/23 annual review that it had undertaken smart water meter trials in 1500 homes. The average water use across Southern Water households was 128 litres per person per day in 2022/23, in line with its forecasts and below the latest national average of 141. The Environment Agency and Defra track whether water companies are effectively reducing water consumption across household and business customers each year and escalate concerns where applicable.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Home Office:
To ask the Secretary of State for the Home Department, what plans he has to update the impact assessment for Electronic Travel Authorisation to include airside transit passengers.
Answered by Tom Pursglove - Minister of State (Minister for Legal Migration and Delivery)
Electronic Travel Authorisations deliver important security benefits. A blanket exemption to the ETA requirement for passengers transiting airside would fundamentally undermine the rationale of the scheme by creating a permission free route of travel into the UK which would be open to abuse.
We will keep our position under review to monitor the impact on transit as the scheme is rolled out.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve genomics testing for bowel cancer patients.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
A National Health Service testing programme is helping to diagnose thousands of people with a genetic condition, Lynch Syndrome, that increases the chance of developing certain cancers including bowel cancer. The national programme ensures all people diagnosed with bowel cancer are offered genomic testing, with a diagnosis for Lynch Syndrome not only helping to guide more personalised cancer treatment but enabling their families and relatives to be offered testing too. Relatives who receive a diagnosis of Lynch Syndrome can be referred to genetic services to discuss regular testing options to help catch any cancers as early as possible, as well as to consider preventive options such as taking aspirin or undergoing risk-reducing surgery.
Genomic testing in the NHS in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD) which outlines the full range of genomic testing offered by the NHS in England including tests for 3,200 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, including testing for bowel cancer patients.
The NHS GMS cancer genomic testing strategy has facilitated a move to a consolidated laboratory network through the seven NHS GLHs delivering more extensive panel testing using cutting edge high throughput Next Generation Sequencing (NGS) technology. For patients, including those with bowel cancer, this technology enables testing for a larger number of genetic variations to give a more precise diagnosis, identify biomarkers to target treatment and opportunities to access innovative medicines, and can support enrolment into molecularly stratified clinical trials.
Testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional (for example, their general practitioner or other healthcare professional if they are already being seen in a relevant service) whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS clinical genomics service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.
The 17 NHS Clinical Genomic Services (NHS CGSs), commissioned by NHS England, deliver a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients of all ages and their families who have, or are at risk of having, a rare genetic or genomic condition. As part of the NHS CGS, the patient and their family will access diagnosis, and management relevant to their particular condition, but also receive support and guidance so that they are able to understand their condition, its implications, and their options in relation to reproduction, screening, prevention and clinical management.